BioWorld

Nov. 11, 2008

ArQule Makes Two Deals with Daiichi in Cancer

ArQule would receive $75 million in up-front cash under two deals with Japan's Daiichi Sankyo Co. Ltd. - one to develop an anticancer compound and the other to discover a new generation of kinase inhibitors for cancer. (BioWorld Today) Read More

LDL Hypothesis Alive and Well; Other Biomarkers also Valuable

Improved T-Cell Receptor Takes on all Comers of HIV Epitope

Moving from Licensing Talks to M&A can be a Tricky Step

Regulatory Hitch to Delay Solzira Filing, Milestone to XenoPort

Other News To Note

Financings Roundup

Clinic Roundup

Today's news in brief

BioWorld

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

SERCA inhibitor from Sumitomo shows promise for MSA-C treatment

BioWorld Science

At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....